Imaging software developer Median Technologies said it has signed a contract to provide software and services for a phase II trial led by an unnamed global biopharmaceutical provider beginning this year.
The project, valued at 1.4 million euros ($1.8 million U.S.) will involve sending image data on 300 patients to more than 100 research sites in 14 countries around the world, the vendor said. The study, focusing on the use of biomarkers in cancer detection and treatment, opens a new phase in the company's push to provide imaging solutions to the biopharmaceutical industry, Median stated.
